NCKU, Duke University researchers successfully implant a new cardiac assist device on calf
Tainan, Taiwan, October 21, 2013
The National Cheng Kung University Heart Science and Medical Devices Research Center (NCKU HSDMRC) and the Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, NC, USA, jointly carried out a cardiac assist device implantation on calf recently.
Dr. Roberto Manson and Dr. Mani Daneshmand from Cardiothoracic Surgery, Duke University Medical Center attended the workshop of Duke-NCKU collaboration on early interventional ventricular assist device hosted by NCKU, October 13-16, and participated in the para-aortic blood pump (PABP) implantation surgery on calf.
NCKU HSDMRC Director Dr. Pong-Jeu Lu, who is also a professor at the NCKU Department of Aeronautics and Astronautics, had led his research team to develop the PABP for over thirteen years.
He said, PABP is a new type of left ventricular assist device which has completed major design, prototype manufacturing and testing after more than 10 years of effort.
This study could be extended to humans where clinical trials are to be conducted within the next two years, which will benefit more patients with heart failure in the future, Dr. Manson noted.
It is worthwhile mentioning that PABP is designed to be implanted in patients with heart failure prior to irreversible stage to hopefully restore heart function, according to Dr. Lu.
However, the most important part would be the minimally invasive surgery, which allows rapid implantation into the aorta without affecting heart functions, thus shortening the recovery time after surgery.
Last year, Dr. Lu’s research team had signed a 3-year Agreement with the Division of Cadiothoracic Surgery, Department of Surgery at Duke University on the research development of cardiac assist device, efficacy and safety regarding surgical treatment on patients with heart failure and the pathway of cell recovery after long-term PABP support.
Dr. Daneshmand and Dr. Manson arrived at NCKU for the first time to attend a 5-day workshop together with NCKU HSDMRC. Both of them are senior chest surgery physicians, having many years of experience in heart and vascular surgery.
“NCKU’s PABP research outcome can be applied on patients with heart failure of non-refractory stage,” noted Dr. Daneshmand who was impressed with NCKU’s latest medical invention. “It can also be used to restore heart function of patients with late stage heart failure and prolong patient’s life with reasonable quality, hence it is a very advanced piece of medical innovation.”
Dr. Manson added, “It is an exciting result that the calf has strong heartbeat after surgery.” The research entering the phase of human trials within two years is foreseeable.
During the workshop, Dr. Lu introduced the research and development progress of PABP, which had been improved for 3 design generations after more than 10 years.
Artificial manifold implant can be rapidly inserted within 3 to 5 minutes, creating only a small wound with a 3mm diameter driveline penetrating through the skin while limiting the implant incision at about 5 to 7 cm in length so as to reduce the post-operative infection.
NCKU HSDMRC researchers carried out a live demonstration on calf, using specially designed tools to temporarily stop blood flow in aorta and rapidly implant PABP in the aorta without bleeding and restoring the aortic circulation. Moreover, the whole implantation was conducted without cardiopulmonary bypass. Strong heartbeat could be seen after the surgery.
Dr. Daneshmand and Dr. Manson then took over to demonstrate many different surgical implantation alternatives, and worked together with Dr. Lu’s research team members to identify the safest and fastest surgical method suitable to human patients.
Enditem/
The National Cheng Kung University Heart Science and Medical Devices Research Center (NCKU HSDMRC) and the Division of Cardiothoracic Surgery, Department of Surgery, Duke University, Durham, NC, USA, jointly carried out a cardiac assist device implantation on calf recently.
Dr. Roberto Manson and Dr. Mani Daneshmand from Cardiothoracic Surgery, Duke University Medical Center attended the workshop of Duke-NCKU collaboration on early interventional ventricular assist device hosted by NCKU, October 13-16, and participated in the para-aortic blood pump (PABP) implantation surgery on calf.
NCKU HSDMRC Director Dr. Pong-Jeu Lu, who is also a professor at the NCKU Department of Aeronautics and Astronautics, had led his research team to develop the PABP for over thirteen years.
He said, PABP is a new type of left ventricular assist device which has completed major design, prototype manufacturing and testing after more than 10 years of effort.
This study could be extended to humans where clinical trials are to be conducted within the next two years, which will benefit more patients with heart failure in the future, Dr. Manson noted.
It is worthwhile mentioning that PABP is designed to be implanted in patients with heart failure prior to irreversible stage to hopefully restore heart function, according to Dr. Lu.
However, the most important part would be the minimally invasive surgery, which allows rapid implantation into the aorta without affecting heart functions, thus shortening the recovery time after surgery.
Last year, Dr. Lu’s research team had signed a 3-year Agreement with the Division of Cadiothoracic Surgery, Department of Surgery at Duke University on the research development of cardiac assist device, efficacy and safety regarding surgical treatment on patients with heart failure and the pathway of cell recovery after long-term PABP support.
Dr. Daneshmand and Dr. Manson arrived at NCKU for the first time to attend a 5-day workshop together with NCKU HSDMRC. Both of them are senior chest surgery physicians, having many years of experience in heart and vascular surgery.
“NCKU’s PABP research outcome can be applied on patients with heart failure of non-refractory stage,” noted Dr. Daneshmand who was impressed with NCKU’s latest medical invention. “It can also be used to restore heart function of patients with late stage heart failure and prolong patient’s life with reasonable quality, hence it is a very advanced piece of medical innovation.”
Dr. Manson added, “It is an exciting result that the calf has strong heartbeat after surgery.” The research entering the phase of human trials within two years is foreseeable.
During the workshop, Dr. Lu introduced the research and development progress of PABP, which had been improved for 3 design generations after more than 10 years.
Artificial manifold implant can be rapidly inserted within 3 to 5 minutes, creating only a small wound with a 3mm diameter driveline penetrating through the skin while limiting the implant incision at about 5 to 7 cm in length so as to reduce the post-operative infection.
NCKU HSDMRC researchers carried out a live demonstration on calf, using specially designed tools to temporarily stop blood flow in aorta and rapidly implant PABP in the aorta without bleeding and restoring the aortic circulation. Moreover, the whole implantation was conducted without cardiopulmonary bypass. Strong heartbeat could be seen after the surgery.
Dr. Daneshmand and Dr. Manson then took over to demonstrate many different surgical implantation alternatives, and worked together with Dr. Lu’s research team members to identify the safest and fastest surgical method suitable to human patients.
Enditem/
Click Num:
Share
